Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McNeil's Motrin Is Second OTC Cleared For Migraine Pain

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare soon will introduce a second indication-specific OTC analgesic - and become the second marketer of an OTC for migraine pain relief - following FDA's Feb. 25 approval of Motrin Migraine Pain.

You may also be interested in...



OTC Migraine Drug Use Slips, But Still Tops Rx Remedies - NHF Survey

Fifty-seven percent of migraine sufferers report only using OTC drugs to treat their headaches, Richard Lipton, MD, Albert Einstein College of Medicine, et al., state in the July/August issue of Headache.

OTC Migraine Drug Use Slips, But Still Tops Rx Remedies - NHF Survey

Fifty-seven percent of migraine sufferers report only using OTC drugs to treat their headaches, Richard Lipton, MD, Albert Einstein College of Medicine, et al., state in the July/August issue of Headache.

OTC Migraine Drug Use Slips, But Still Tops Rx Remedies - NHF Survey

Fifty-seven percent of migraine sufferers report only using OTC drugs to treat their headaches, Richard Lipton, MD, Albert Einstein College of Medicine, et al., state in the July/August issue of Headache.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel